argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 dec 2015 - 07:05
Statutaire naam
argenx SE
Titel
argenx to host workshop and webcast announcing topline clinical TCL data and preclinical AML data from ARGX-110 program
Bericht
Workshop and webcast to occur at 12:00 pm ET today
Breda, the Netherlands / Ghent, Belgium, 7 December 2015 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that it will host a workshop and webcast to discuss new ARGX-110 data, in conjunction with the American Society of Hematology (ASH) Annual Meeting. The data on ARGX-110, a novel anti-CD70 therapeutic antibody, include topline clinical results in T-cell lymphoma (TCL) and preclinical data in acute myelogenous leukemia (AML).
Datum laatste update: 27 juli 2024